Complications Within 6 Months After Arthroscopic Rotator Cuff Repair: Registry-Based Evaluation According to a Core Event Set and Severity Grading.


Journal

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association
ISSN: 1526-3231
Titre abrégé: Arthroscopy
Pays: United States
ID NLM: 8506498

Informations de publication

Date de publication:
01 2021
Historique:
received: 07 02 2020
revised: 13 08 2020
accepted: 13 08 2020
pubmed: 25 8 2020
medline: 5 6 2021
entrez: 25 8 2020
Statut: ppublish

Résumé

To report complications after arthroscopic rotator cuff repairs (ARCRs) in a large patient cohort based on clinical application of a newly defined core event set (CES) and severity grading. Consecutive primary ARCRs documented in a local clinical registry between February 2010 and September 2016 were included. Clinicians documented adverse events (AEs) reported until the final, 6-month postoperative follow-up according to the CES. The CES is an organized list of relevant AEs sorted into 3 intraoperative event groups (device, osteochondral, and soft tissue) and 9 postoperative event groups (device, osteochondral, pain, rotator cuff, surgical-site infection, peripheral neurologic, vascular, superficial soft tissue, and deep soft tissue). Severity was determined using an adaptation of the Clavien-Dindo classification. Cumulative complication risks were calculated per event group and stratified by severity and rotator cuff tear extent. A total of 1,661 repairs were documented in 1,594 patients (mean age, 57 years [standard deviation, 9 years]; 38% women); 21% involved partial tears. All events were recorded according to the CES. Intraoperative events occurred in 2.2% of repairs. We identified 329 postoperative events in 307 repairs (305 patients); 93% had 1 AE. The cumulative AE risk at 6 months was 18.5%; AE risks were 21.8% for partial tears, 15.8% for full-thickness single-tendon tears, 18.0% for tears with 2 ruptured tendons, and 25.6% for tears with 3 ruptured tendons. AE risks per event group were as follows: 9.4% for deep soft tissue, with shoulder stiffness (7.6%) being the most common event; 3.4% for persistent or worsening pain; 3.1% for rotator cuff defects; 1.7% for neurologic lesions; 0.8% for surgical-site infection; 0.7% for device; 0.4% for osteochondral; 0.2% for superficial soft tissue, and 0.1% for vascular. Most AEs had severity grades I (160 [49%]) and II (117 [36%]). Comprehensive local AE documentation according to the CES and severity grading was possible and showed that about one-fifth of ARCRs were affected, mostly by one AE of low severity. Shoulder stiffness was the most frequent event. Level IV, case series.

Identifiants

pubmed: 32835815
pii: S0749-8063(20)30688-5
doi: 10.1016/j.arthro.2020.08.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

50-58

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Quinten Felsch (Q)

Shoulder and Elbow Surgery, Schulthess Klinik, Zurich, Switzerland.

Victoria Mai (V)

Shoulder and Elbow Surgery, Schulthess Klinik, Zurich, Switzerland.

Holger Durchholz (H)

Research and Development, Schulthess Klinik, Zurich, Switzerland; Klinik Gut, St Moritz, Switzerland.

Matthias Flury (M)

Center for Orthopedics & Neurosurgery, In-Motion, Wallisellen, Switzerland.

Maximilian Lenz (M)

Shoulder and Elbow Surgery, Schulthess Klinik, Zurich, Switzerland.

Carl Capellen (C)

Shoulder and Elbow Surgery, Schulthess Klinik, Zurich, Switzerland.

Laurent Audigé (L)

Shoulder and Elbow Surgery, Schulthess Klinik, Zurich, Switzerland; Research and Development, Schulthess Klinik, Zurich, Switzerland; Department of Orthopaedic Surgery and Traumatology, University Hospital of Basel, Basel, Switzerland. Electronic address: laurent.audige@kws.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH